about
Pancreatic solitary and synchronous metastasis from breast cancer: a case report and systematic review of controversies in diagnosis and treatment.Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.Phase II study of rubitecan in recurrent or metastatic head and neck cancer.Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer.Sunitinib in metastatic renal cell carcinoma patients with brain metastases.Real-world study of everolimus in advanced progressive neuroendocrine tumors.Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib.Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis surveyBone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?Panitumumab a novel drug in cancer treatment.Sunitinib: bridging present and future cancer treatment.Erlotinib-induced complete response in a patient with epidermal growth factor receptor wild-type lung adenocarcinoma after chemotherapy failure: a case report.The therapy of kidney cancer with biomolecular drugs.Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicity.Novel agents, combinations and sequences for the treatment of advanced renal cell carcinoma: When is the revolution coming?Clinical management of metastatic kidney cancer: the role of new molecular drugs.Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study.High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma.A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patients.Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.The treating scenario in genitourinary oncology: what is new? Part 1.The treating scenario in genitourinary oncology: what is new? Part 2.Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung canFOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM).Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort.Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era.We need both randomized trials and real-world data: the example of everolimus as second-line therapy for mRCC.Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.Horner's syndrome: An unusual presentation of metastatic disease in breast cancer.Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.
P50
Q30725747-57CF7847-C9AC-4355-9F85-23645F245943Q33361491-82D5479E-278F-458B-B371-5714D774A83AQ33366660-ACD0DAA1-E6A4-4C4E-9A4F-A316A989B265Q33376733-5E4A9123-282C-4E6A-86EB-46B12CBD7642Q33390463-2F3FDD46-190C-4528-A4E1-B2AFFD5E98D5Q33391978-E201D8DC-B5CA-49D2-8D91-49CE32744FC1Q33417013-81A75DB7-4547-428D-9B60-A87A7C03C1F0Q33419797-34794468-1237-473B-8A21-808553E6C4A8Q33423740-B856D78B-EB87-405E-8C0F-ED1F8C4C93ECQ34617300-653374F3-70B2-4A76-9809-8607FEA8FA25Q34660799-E1697353-4EA8-4E67-ABE0-51E94CD17BA8Q34890900-6C17E7E2-46B0-4EBD-9BED-AEBF7051ED14Q35080143-DBEFCFE1-57B2-426D-AC80-DAD025C75747Q35083485-7AB13D3E-903C-4B59-8490-327F3AC0FF8CQ35464515-00D84BD8-4A9A-4920-B31D-4ABDB6726EB1Q36860158-0EDE9C35-1EFE-44B7-8841-70C3E6B9794AQ36860188-4F39381B-441D-4C0E-8A95-F56EC57DBAA3Q37689074-8D5FBFBD-AA32-4AA2-85FC-AAF1D8D92681Q37815605-A5C35631-39B8-43FA-AE53-080A9E1133E1Q38013163-A038CBDA-0AFA-43FD-9EFD-43D8CBFD8BB8Q38063351-7B0DD42E-9B51-4F3D-A128-5CEC0F118A7FQ38652566-E35BCFE2-5B01-47A3-91C7-9F101785C7F0Q38919065-C8C78A38-8A5D-47BB-847A-17074F1D8736Q39150764-E9D704F6-19F4-4670-8646-B55EC1FB9CD7Q39371808-E18B83EB-6FEF-4236-9CD2-752AE285527CQ41644108-8E3B7472-3095-4DA2-A3AE-FDEB650CEF36Q41652822-53166654-0D39-49B3-A246-94EF984DD0E4Q42596667-37E6203B-F3DB-4281-BF46-04FB4F2FFB5DQ43299267-B861BD13-7ABF-4E10-8BEC-D8FDF6EEE6E5Q44834803-79C6EB32-7958-43AA-82E2-5358E4E3EFD8Q45968992-EA51DB3F-C5E8-42F8-A8E0-D5973CE7B861Q46093018-D1507E7F-AEA1-4E00-90D2-B55834FC9C6EQ46516635-739D8824-8F27-42A9-9894-48E388AFFD24Q46705692-0EC722BF-CFB0-4380-A2B9-1373DEB85260Q48391442-3FB4DF51-7849-45EE-BFBC-BB06F87A0041Q48849601-15AFC6AA-2089-496D-9D04-D3FEA3DAC974Q51217838-5089FC1D-89DF-4761-803B-86086712386AQ53196730-3BE5F6B9-0A24-4F22-AB82-0B300AB997ECQ53332957-E4F3403C-4B56-4562-9807-26C5068FB583Q53505725-3AF30DBC-F41A-4A08-8364-6658B7C33FC8
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giacomo Cartenì
@ast
Giacomo Cartenì
@en
Giacomo Cartenì
@es
Giacomo Cartenì
@nl
Giacomo Cartenì
@sl
type
label
Giacomo Cartenì
@ast
Giacomo Cartenì
@en
Giacomo Cartenì
@es
Giacomo Cartenì
@nl
Giacomo Cartenì
@sl
prefLabel
Giacomo Cartenì
@ast
Giacomo Cartenì
@en
Giacomo Cartenì
@es
Giacomo Cartenì
@nl
Giacomo Cartenì
@sl
P1053
K-5810-2016
P106
P1153
6602125113
P21
P31
P3829
P496
0000-0003-1441-6376